STERIS (STE)
(Delayed Data from NYSE)
$225.18 USD
+3.33 (1.50%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $225.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$225.18 USD
+3.33 (1.50%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $225.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Zacks News
Steris (STE) Down 0.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STERIS (STE) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in Q1.
Steris (STE) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 10.81% and 3.46%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet (PODD) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Insulet (PODD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
TFX or STE: Which is a Better Investment Pick Right Now?
by Zacks Equity Research
STERIS (STE) scores higher than Teleflex (TFX) when it comes to valuation and one-year price performance.
Steris (STE) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STERIS (STE) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in the reported quarter.
Steris (STE) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 6.25% and 4.62%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Aurora Cannabis (ACB) in Q3 Earnings?
by Zacks Equity Research
Continued execution of consumer and medical strategies, launch of new products and strong international footprint are likely to aid Aurora Cannabis (ACB) in Q3.
Steris (STE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Core Business Unit Fuel McKesson (MCK) Q4 Earnings?
by Zacks Equity Research
Anticipated growth across core business unit and solid show by Medical Surgical and European Pharmaceutical Solutions is likely to aid McKesson's (MCK) Q4 earnings. However, rising costs might be a dampener.
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Better-than-expected performance at Pharmaceutical and Medical segments and diverse product portfolio is likely to aid Cardinal Health (CAH) in Q3 earnings. However, stiff competition might play spoilsport.
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
Better-than-expected performance at Kidney Care, strategic buyouts and international expansion might aid DaVita (DVA) in Q1. However, integration risks might be a dampener.
Masimo Gets CE Mark for ANI Module, Enhances Root Platform
by Zacks Equity Research
Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.
What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?
by Zacks Equity Research
Better-than-expected performance at Pharmaceutical Distribution and World Courier and higher revenues might aid AmerisourceBergen (ABC) in Q2 earnings. However, stiff competition might be a dampener.
Can Mass Cytometry Drive Fluidigm's (FLDM) Q1 Earnings?
by Zacks Equity Research
Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.
DENTSPLY SIRONA (XRAY) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher Consumable revenues, product innovation and focus on R&D likely to aid DENTSPLY SIRONA (XRAY) in Q1 earnings. However, contraction is gross margin might be a dampener.
Integer Holdings (ITGR) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Better-than-expected performance at C&V and Cardiac & Neuromodulation product lines and higher revenues might aid Integer Holdings (ITGR) in Q1. But decline in non-medical sales might be a dampener.
Here's Why You Should Hold on to STERIS (STE) Stock Now
by Zacks Equity Research
STERIS (STE) has been gaining investors' confidence on consistently positive results.
STERIS (STE) Margin Pressure Hurts, Strategic Growth High
by Zacks Equity Research
Mounting operating expenses are weighing on the bottom line of STERIS (STE).
Why Is Steris (STE) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q3.
Steris (STE) Matches Q3 Earnings Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 0.00% and 1.21%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.